Search Within

Alyson Merced

Formats
  1. Meeting Abstract (8)
  2. Journal Article (5)
Groups
  1. Breast Medicine Service (13)
  2. Department of Medicine (13)
  3. Solid Tumor Oncology Division (13)
  4. Survivorship Research (13)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (12)
  6. Biostatistics Service (11)

More Groups

People
  1. Clifford Hudis (13)
  2. Larry Norton (12)
  3. Sujata Patil (11)
  4. Chau Dang (10)
  5. Patrick Morris (10)
  6. Carol Chen (6)

More People

Years
  1. 2013 (3)
  2. 2011 (5)
  3. 2010 (5)
Publications
  1. Journal of Clinical Oncology (8)
  2. Annals of Oncology (1)
  3. Cancer (1)
  4. Cancer Research (1)
  5. Clinical Breast Cancer (1)
  6. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (8)
  2. American Association for Cancer Research (2)
  3. Elsevier Inc. (1)
  4. Oxford University Press (1)
  5. Wiley Blackwell (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Morris, P. G.; Iyengar, N. M.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R. J.; Steingart, R.; Oeffinger, K. C.; Lin, N.; Moy, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Morris, P. G.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R. J.; Steingart, R.; Oeffinger, K. C.; Lin, N. U.; Moy, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
    Journal Article

    Morris, P. G.; Iyengar, N. M.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R.; Steingart, R.; Oeffinger, K. C.; Lin, N.; Moy, B.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR-metastatic breast cancer (MBC)
    Meeting Abstract

    Gucalp, A.; Tolaney, S. M.; Isakoff, S. J.; Ingle, J. N.; Liu, M. C.; Carey, L. A.; Blackwell, K. L.; Rugo, H. S.; Nabell, L.; Abbruzzi, A.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Dang, C. T.; Morris, P. G.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R.; Steingart, R.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
    Journal Article

    Gucalp, A.; Sparano, J. A.; Caravelli, J.; Santamauro, J.; Patil, S.; Abbruzzi, A.; Pellegrino, C.; Bromberg, J.; Dang, C.; Theodoulou, M.; more...
    Clinical Breast Cancer (2011)

    Fulltext@MSK | Save
  • A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
    Journal Article

    Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Journal Article

    Morris, P. G.; Chen, C.; Steingart, R.; Fleisher, M.; Lin, N.; Moy, B.; Come, S.; Sugarman, S.; Abbruzzi, A.; Lehman, R.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Traina, T. A.; Sparano, J. A.; Caravelli, J.; Patil, S.; Abbruzzi, A.; Hawke, R.; Bromberg, J.; Nonemaker, J.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save